Immuneering Corp (IMRX NASDAQ) stock market data APIs
$2.5434
0.41(16.1%)
as of June 20, 2025
Try our APIs with
free plan!
Immuneering Corp Financial Data Overview
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Prev. Close
2.5434
Open
2.9514
High
3.0651
Low
2.3835
52 wk Range
1-3.83
Market Cap
92 123 K
Shares Outstanding
35 986 K
Revenue
455
EPS
-0.42
Beta
0.002
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Immuneering Corp data using free add-ons & libraries
Get Immuneering Corp Fundamental Data
Immuneering Corp Fundamental data includes:
- Net Revenue: 455
- EBITDA: -63 850 176
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: -0.585
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immuneering Corp News
New
Immuneering director Schall buys $89k in IMRX stock
Director Thomas J. Schall of Immuneering Corp (NASDAQ:IMRX) recently purchased 40,485 shares of Class A Common Stock, according to a Form 4 filing with the Securities and Exchange Commission. The tr...
Immuneering stock price target raised to $10 at Mizuho on cancer drug data
Mizuho raised its price target on Immuneering Corporation (NASDAQ:IMRX) to $10.00 from $8.00 on Wednesday, while maintaining an Outperform rating following positive clinical trial results for the co...
Immuneering stock rises after positive pancreatic cancer trial data
Investing.com -- Immuneering Corporation (NASDAQ:IMRX) stock rose 7% on Monday after the clinical-stage oncology company reported positive survival data from its ongoing Phase 2a trial evaluating at...
Why Immuneering Is Rising In Pre-market?
(RTTNews) - Immuneering (IMRX) announced positive data from ongoing Phase 2a clinical trial evaluating atebimetinib, an oral, once-daily MEK inhibitor, in combination with modified gemcitabine/nab-pac...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
